
News|Articles|February 28, 2025
Executive Summary: Leveraging the Evolving Bioequivalence Regulatory Landscape to Enhance Inhaled Product Design and Development
Author(s)Vectura Group plc, Vectura
The regulatory landscape for bioequivalence continues to evolve, leveraging a broader suite of characterization techniques. These not only provide deeper product understanding, but also utility for generic product development as the potential for replacement of costly clinical studies becomes more of a reality.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025
2
CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor
3
Is Pharma Solving the Right Problem with its Data Transformation Efforts?
4
Multi-Compendial Compliance for Pharmaceutical Excipients–Part 1: A Practical Application of Specification Equivalence
5